Quarterlies Round-Up: Varian maintains progress as Rita Medical sees improvements
This article was originally published in Clinica
Executive Summary
Cholestech's first quarter revenues were negatively impacted by the company's decision, announced at the end of fiscal 2004, to eliminate quarter-end discounts for distributors that make large volume purchases. The Californian diagnostics developer believes that sales to its product distributors are now normalised with sales to end-users and expects revenue growth in excess of 10% for the remaining nine months of fiscal 2005. The company is also expecting a further boost to its cholesterol and diabetes franchises from January 2005 onwards, once the US Prescription Drug and Medicare Improvement Act of 2003 is implemented, and reimbursement for cholesterol and diabetes screening will be provided.
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.